STAT+: Pharmalittle: The ‘godfather’ of biotech trying to save Biogen; pharma companies grapple with ADHD drug shortages
Happy Monday, folks — Allison DeAngelis here. Ed is away from the Pharmalot campus this week. But I just moved in, and while I figure out which poster to hang on my dorm room walls, I’m going to update you on the latest news.
Stelios Papadopoulos has spent the past four decades becoming the living embodiment of biotech’s institutional memory. Now, at the summit of a career spanning most of biotech’s recorded history, Papadopoulos faces a challenge that will color his legacy, according to STAT. As chairman of the board at Biogen, the industry veteran is charged with turning the storied company around over the course of what will be a decisive year.
Continue to STAT+ to read the full story…
